United States Patent & Trademark Office (USPTO) has granted Cesca Therapeutics the first two of a family of patent applications related to its proprietary methods for the treatment of ischemic cardiovascular disorders, such as critical limb ischemia (CLI) and acute myocardial infarction (AMI).
The patents numbered 9,393,269 and 9,402,867 protect important components of Cesca’s SurgWerks technology platform, which is designed for the delivery of autologous regenerative stem cell therapies in a point-of-care environment.
The firm previously announced that the SurgWerks platform had been approved by the FDA for use in Cesca’s phase III, pivotal trial for the treatment of late-stage, poor option and no option CLI patients.
Cesca’s director of clinical research Dalip Sethi said: “We have been focused on developing and refining our methods for the optimal handling of cells throughout the surgical procedure to ensure their viability and potency, as well as optimising the delivery method to minimise shear stress on the cells.
“These patents reinforce the initial design and proof-of-concept work related to the use of our SurgWerks platform in a point-of-care setting, further strengthening our intellectual property portfolio as we continue our discussions with the FDA in order to move ahead with our phase III trial for CLI in the near future.”
The patent claims include rapid concentration and delivery of bone marrow derived stem and progenitor cells such as hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), endothelial progenitor cells (EPCs) and CXCR4 positive cells with a reduced amount of red blood cells (RBCs).
The SurgWerks processing platform comprises a smart cell processing module for optically monitored separation and concentration of cell components of interest during centrifugal fractionation.